NCT06239220 2026-02-27
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Dana-Farber Cancer Institute
Phase 2 Recruiting
Dana-Farber Cancer Institute
Essen Biotech
Masonic Cancer Center, University of Minnesota
Instituto de Investigación Hospital Universitario La Paz
Masonic Cancer Center, University of Minnesota